Testing TQB6426 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called TQB6426 for people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called GPC3 found on some tumors, aiming to deliver a powerful therapy directly to the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor that has not responded to previous treatments.
- For the expansion part of the trial, your tumor must test positive for a protein called GPC3 (a prior test result is okay).
- You are generally healthy enough for daily activities (ECOG score 0 or 1) and your doctor expects you to live more than 12 weeks.
- Your liver and kidney function, blood counts, and other lab tests are within acceptable ranges.
- You have not had prior treatment with a GPC3-targeted drug or a specific type of antibody-drug conjugate (ADC).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called TQB6411 for people with advanced esophageal cancer that has worsened after prior treatment. The hope is that it may shrink tumors or slow the cancer's growth.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
This phase 1 trial tests an experimental drug called TQB2252 for people with advanced cancers that have not responded to standard treatments. The drug blocks a protein called LAG3 to help the immune system attack cancer cells.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.